New hope for tough leukemia: CT0991 trial launches
NCT ID NCT06709131
First seen Jan 04, 2026 · Last updated May 17, 2026 · Updated 23 times
Summary
This early-stage study tests a new drug, CT0991, in 24 adults with acute myeloid leukemia that has come back or not responded to treatment. The main goals are to check safety, find the right dose, and see if it helps control the disease. Participants must be 18-75 years old and in relatively good health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA(AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The first affiliated hospital of medical college of zhejiang university
Hangzhou, Zhejiang, 310003, China
Conditions
Explore the condition pages connected to this study.